Abstract
This represented the first serious publication indicating the potential utility of sildenafil in the treatment of erectile dysfunction (ED). It represented the arrival of oral therapy for the treatment of ED, offering much hope to patients and physicians alike.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
11.1 Key Trial References
11.1.1 Major Publication
Boolell M, Allen M, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8:47–52, 1996.
11.1.2 Other Important Publications
Boolell M, Gepi-Attee S, et al. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 78:257–261, 1996.
Olsson A, Speakman M, et al. Sildenafil citrate (Viagra) is effective and well tolerated for treating erectile dysfunction of psychogenic or mixed aetiology. Int J Clin Pract 54(9):561–566, 2000.
Eardley I, Morgan R, et al. Efficacy and safety of sildenafil citrate in the treatment of men with mild to moderate erectile dysfunction. Br J Psychiat 178:325–330, 2001.
Rights and permissions
Copyright information
© 2007 Springer-Verlag London Limited
About this chapter
Cite this chapter
(2007). First Clinical Data on Sildenafil: The Arrival of Oral Pharmacotherapy. In: Key Clinical Trials in Erectile Dysfunction. Springer, London. https://doi.org/10.1007/978-1-84628-428-1_11
Download citation
DOI: https://doi.org/10.1007/978-1-84628-428-1_11
Publisher Name: Springer, London
Print ISBN: 978-1-84628-427-4
Online ISBN: 978-1-84628-428-1
eBook Packages: MedicineMedicine (R0)